GALNT2 and cervical cancer: Our data demonstrate that concomitant high expression of GALNT2 and cytokines (IL1A, IL1B, IL11), chemokines (CXCL1, CXCL2, CXCL5, CXCL6, CXCR1 or CCR3) or immune modulatory molecules (CD47, CD274, CD276, CSF1R, TNFSF9 and TNFSF11) could predict worse survival of cervical cancer patients, compared with their corresponding low or mixed expression groups.